Projects per year
A phase 3, open-label, randomised study to compare the efficacy and safety of luspatercept (Ace-536) versus epoetin alfa for the treatment of anaemia due to Ipss-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions [ACE-536-MDS-002]
Kenealy, M. & Baker, E.
20/12/18 → 31/12/24
Research Output per year
Complete remission of Waldenström's associated generalized crystal-storing histiocytosis of IgM lambda subtype with bortezomib-based combination chemotherapyBaird, S. M., Kenealy, M. K. & Hoy, R., 2 Nov 2015, In : Leukemia and Lymphoma. 56, 11, p. 3233-3235 3 p.
Research output: Contribution to journal › Letter › Other › peer-review